Q-omics provides the consensus-scored UBE2E1 profile across patient tissues and cancer cell-line models. UBE2E1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2E1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, UBE2E1 RNA expression shows 19,138 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, and ACC as cancer lineages where UBE2E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2E1 survival associations across molecular data types. UBE2E1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2E1 RNA expression–survival associations across cancer types. High UBE2E1 expression shows unfavorable associations in LIHC, ACC, SARC and KICH, but favorable associations in UVM and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2E1 RNA expression.
This table summarizes UBE2E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2E1 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, BRCA, CHOL and READ. The LIHC box plot shows higher UBE2E1 RNA expression in tumor versus normal tissue (log2 FC = +0.821, t-test p < 0.001).
This table shows molecular features associated with UBE2E1 in patient tissues and cancer cell lines. In patient samples, UBE2E1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
